Edoxaban Review Spurs FDA Call For Changes In Anticoagulant Trials
Executive Summary
Agency staff recommend separate assessment of ischemic and hemorrhagic strokes, and exposure-targeting of therapeutic blood levels; cardio-renal panel endorses Daiichi Sankyo’s Factor Xa inhibitor for atrial fibrillation, but concerns about reduced efficacy in normal renal function patients may result in a competitively disadvantaged label.
You may also be interested in...
BMJ’s Pradaxa Exposé Includes Wider Call For Monitoring Of All New Anticoagulants
British Medical Journal investigation focuses mainly on Boehringer’s direct thrombin inhibitor Pradaxa, but also suggests that all novel anticoagulants could benefit from testing to ensure the right anticoagulant dose is being given, for safety’s sake.
Regulatory Flexibility: BrainStorm’s Problematic NurOwn BLA May Be A Bridge Too Far For US FDA
Litany of deficiencies, including product quality shortcomings and a failed Phase III clinical efficacy study, may make it impossible for the agency to exercise the type of flexibility it has with the approval of other treatments for ALS and neurodegenerative diseases.